BTIG lowers Tvardi Therapeutics stock price target to $15 on IPF trial setback

Date:

Share post:




BTIG lowers Tvardi Therapeutics stock price target to $15 on IPF trial setback

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Second liens appear on 16% of U.S. mortgages

The share of primary mortgages on properties that also have second liens is currently in the double...

Asia rolls out 4-day weeks, work-from-home to solve fuel crisis caused by Iran war

Closed schools. Work-from-home demands. Price caps.Asia’s governments are scrambling to manage a fuel shortage caused by high...

Healthcare Uses Specialized Language. It Needs Specialized AI, Too.

Healthcare has always struggled with translation. Not between English and other languages but between the dialects spoken...

Bilt 2.0 Charging 0.2% Foreign Transaction Fee, Despite Advertising No Fee

One of the advertised benefits of the Bilt Cardless (Bilt 2.0) cards is no foreign transaction fees....